Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women.
BACKGROUND
Low bone mineral density (BMD) is commonly reported in young men and women with HIV infection, and fracture rates may be higher. With effective antiretroviral therapy (ART), the HIV population is aging. However, little is known about the skeletal status of postmenopausal women.


OBJECTIVE
We aimed to assess the effects of HIV infection and ART on BMD and bone turnover in postmenopausal minority women.


METHODS
A prospective cohort study was performed in 92 HIV+ and 95 HIV- postmenopausal Hispanic and African-American women.


METHODS
We measured BMD by dual-energy x-ray absorptiometry, fracture prevalence, serum levels of inflammatory cytokines (TNFalpha, IL-6), bone turnover markers, calciotropic hormones, and estrone.


RESULTS
HIV+ women were younger (56 +/- 1 vs. 60 +/- 1 yr; P < 0.01) and had lower BMI (28 +/- 1 vs. 30 +/- 1 kg/m(2); P < 0.01) and estrone levels. Prevalence of T scores below -1.0 was greater in HIV+ women at the spine (78 vs. 64%; P < 0.05), total hip (45 vs. 29%; P < 0.05), and femoral neck (64 vs. 46%; P < 0.05), and Z scores adjusted for BMI were lower in HIV+ women at the same sites. Serum TNFalpha, N-telopeptide, and C-telopeptide were significantly higher in HIV+ than HIV- women, particularly those receiving ART. HIV+ status was independently and negatively associated with spine and hip BMD after adjustment for age, ethnicity, BMI, and alcohol.


CONCLUSIONS
The lower BMD, higher prevalence of low BMD, and higher levels of bone turnover markers detected in HIV+ postmenopausal minority women could place them at high risk for future fractures.
Yin
Michael T
MT
M.S., Division of Infectious Diseases, Columbia University Medical Center, 630 West 168th Street, PH8-876, New York, New York 10032, USA. Mty4@columbia.edu
McMahon
Don J
DJ
Ferris
David C
DC
Zhang
Chiyuan A
CA
Shu
Aimee
A
Staron
Ronald
R
Colon
Ivelisse
I
Laurence
Jeffrey
J
Dobkin
Jay F
JF
Hammer
Scott M
SM
Shane
Elizabeth
E
D019380:Anti-HIV Agents / Q000627:therapeutic use; D015519:Bone Density; D016723:Bone Remodeling; D015331:Cohort Studies; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008875:Middle Aged; D017698:Postmenopause / Q000378:metabolism*; D011446:Prospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D019380:Anti-HIV Agents; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha